ABSCI CORP (ABSI) Stock News
NASDAQ:ABSI - Nasdaq - US00091E1091 - Common Stock - Currency: USD
ABSI Latest News, Press Relases and Analysis
Absci to Report Business Updates and First Quarter 2025 Financial and Operating Results on May 13, 2025
VANCOUVER, Wash. and NEW YORK, April 14, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company,...
Absci to Report Business Updates and First Quarter 2025 Financial and Operating Results on May 13, 2025
Nvidia-Backed Recursion, Ginkgo Bioworks Rally Following FDA's Decision To End Animal Testing
FDA announces plan to end mandatory animal testing of new drugs, replacing it with more effective and human relevant methods.
Which Healthcare Stock Is the Best Buy Right Now?
Healthcare stocks provide a combination of upstarts with a high risk, high reward proposition to established firms that can be a defensive maneuver.
Absci to Participate in Upcoming Investor Conferences
Absci Reports Business Updates and Fourth Quarter and Full Year 2024 Financial and Operating Results
Unveiled updates across proprietary pipeline and demonstrated new breakthroughs by AI platform at 2024 R&D Day Entered into collaboration with AMD,...
Absci Reports Business Updates and Fourth Quarter and Full Year 2024 Financial and Operating Results
Absci to Report Business Updates and Fourth Quarter and Full Year 2024 Financial and Operating Results on March 18, 2025
VANCOUVER, Wash. and NEW YORK, March 04, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company,...
Absci to Report Business Updates and Fourth Quarter and Full Year 2024 Financial and Operating Results on March 18, 2025
Absci Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
VANCOUVER, Wash. and NEW YORK, March 04, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company,...
Absci Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Absci to Participate in the KeyBanc Capital Markets Healthcare Forum
VANCOUVER, Wash. and NEW YORK, March 04, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company,...
Absci to Participate in the KeyBanc Capital Markets Healthcare Forum
Absci to Participate in the TD Cowen 45th Annual Health Care Conference
VANCOUVER, Wash. and NEW YORK, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company,...
Absci to Participate in the TD Cowen 45th Annual Health Care Conference
Analyst Praises AMD-Partner Absci's Practical Approach, Sees 118% Stock Upside
Needham analyst has initiated coverage on Absci Corporation (NASDAQ:ABSI), a drug and target discovery company that harnesses deep learning AI and synthetic biology to expand proteins’ therapeutic potential. The rapid growth of artificial intelligence/machine learning (AI/ML) has led to the emergence of numerous companies that are difficult to tell apart. This challenge is worsened by the fact that clinical proof of concept (POC) in this area is still years away. Recently, Absci entered into a s
Mentions: AMD
Absci to Participate in the Guggenheim Securities SMID Cap Biotech Conference
VANCOUVER, Wash. and NEW YORK, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company,...